Marc Machaalani, MD on MAdCAM-1 - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Marc Machaalani, MD on MAdCAM-1

Kidney cancer research at ESMO25: Dana-Farber's Marc Machaalani, MD, shares 3 key takeaways from his presentation on the protein MAdCAM-1 and its ability to predict outcomes in patients with metastatic renal cell carcinoma.

  • November 5, 2025

Share

  • 1

    Circulating MAdCAM-1 levels are prognostic of clinical outcomes in metastatic renal cell carcinoma across three independent clinical trials.

  • 2

    MAdCAM-1 serves as a dynamic biomarker for tracking gut dysbiosis-driven immune dysregulation.

  • 3

    The MAdCAM-1 pathway could be explored as a therapeutic target for microbiota-directed interventions.

  • 4

    Improving outcomes in treatment-resistant renal cell carcinoma may involve targeting the MAdCAM-1 pathway.

  • 5

    Research presented by Marc Machaalani, MD, highlights the significance of MAdCAM-1 in kidney cancer prognosis and treatment.

Original Source(s)

Marc Machaalani, MD on MAdCAM-1

  • November 5, 2025

Related Content

Sesquiterpenoids influence IFIT protein family and LIMK1: potential effects on the tumor microenvironment and macrophage infiltration

Impact of Azygos Venous Pathway Status on Surgical Difficulty in Patients with Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus: A Retrospective Study with a Large Cohort from China

International Kidney Cancer Collaboration with Leadership from Philadelphia

Kidney cancer is a growing global health problem, and both clinicians and policymakers need to prepare for a steep rise in the number of cases,” said Alexander Kutikov, MD, FACS, Chair of the Department of Urology at Fox Chase Cancer Center, and senior author of a landmark international study published in European Urology, which demonstrates that if current trends continue, kidney cancer cases could double by 2050

  • December 2, 2025

  • 3 min